EndoSound

EndoSound is trying to solve a problem that most patients never realize exists.

While endoscopic ultrasound (EUS) is one of the best tools available for detecting diseases like pancreatic cancer, liver disease, and gastrointestinal tumors, it's typically available only at large hospitals. That’s because the equipment is expensive, specialized, and requires dedicated endoscopes. As a result, many community hospitals and outpatient surgery centers simply don't offer it.

The Oregon-based medtech company has developed a more affordable alternative. Instead of requiring physicians to purchase entirely new endoscopes, EndoSound's system adds ultrasound capability to the standard gastroscopes already used in thousands of endoscopy suites. The result is a lower-cost way for doctors to perform advanced imaging without dramatically changing their workflow.

EndoSound has raised more than $12 million from professional investors and strategic partners. This includes venture-firm GeoMedTech and the American Gastroenterological Association's GI Opportunity Fund. The company has also signed a $5 million licensing agreement with a major gastrointestinal medical-device company.

To understand why that matters, it helps to know how endoscopic ultrasound works. During a traditional endoscopy, physicians insert a flexible tube equipped with a camera into a patient's digestive tract. That allows them to see the surface of organs like the stomach and esophagus.

Endoscopic ultrasound goes a step further by adding an ultrasound probe to the tip of the scope, allowing doctors to see beneath the surface and examine nearby organs, lymph nodes, and tissue. This makes it much easier to detect pancreatic cancer, liver disease, cysts, tumors, and other abnormalities at earlier stages.

The problem is cost. Conventional EUS systems require specialized equipment that can cost hundreds of thousands of dollars, limiting access primarily to major medical centers. EndoSound's Vision System is designed to deliver many of the same diagnostic capabilities using equipment physicians already own. That significantly lowers the financial barrier for outpatient surgery centers and community hospitals while potentially allowing many more patients to receive advanced diagnostic imaging closer to home.

The opportunity is sizable. EndoSound estimates it's pursuing a global market worth roughly $20 billion spanning gastrointestinal diagnostics and echo-endoscopy. Several long-term trends are working in its favor, including an aging population, rising rates of digestive diseases, and increasing emphasis on earlier cancer detection. As healthcare systems continue shifting more procedures away from hospitals and into lower-cost outpatient settings, demand for affordable imaging technologies could continue growing.

EndoSound’s business model combines equipment sales with recurring revenue. Healthcare providers purchase the company's imaging system for approximately $60,000. After that, EndoSound generates ongoing revenue through disposable components and procedure-related products that average roughly $650 per use. That creates a "razor-and-blade" model in which every additional procedure performed can generate recurring income after the initial equipment sale.

The company’s technology has received both FDA clearance and the FDA's Breakthrough Device designation. More than 1,000 procedures have been performed using the system, with reported clinical acceptance exceeding 95%. EndoSound has also built a substantial intellectual property portfolio that includes 10 issued patents and another 10 patent applications. In 2022, the American Society for Gastrointestinal Endoscopy recognized the company with its GI Innovation of the Year award.

The leadership team also brings relevant commercialization experience. Co-founder and CTO Scott Corbett previously founded MicroConnex, a medical-device manufacturing company that was ultimately acquired by Carlisle Interconnect Technologies.

Team Background

Scott Aldrich - Chief Executive Officer

Scott joined EndoSound as CEO in 2024 after spending more than two decades commercializing medical technologies. Throughout his career, he has helped launch numerous medical-device products in the U.S. and international markets, with a particular focus on gastroenterology and advanced medical imaging.

Before joining EndoSound, he served as Vice President of Commercial and Strategy at Motus GI, a publicly traded medical-device company developing technologies for gastrointestinal procedures. Earlier, he held leadership roles at Mauna Kea Technologies, where he helped commercialize the Cellvizio imaging platform, and at PENTAX Medical, a leading manufacturer of endoscopy equipment. He also held senior marketing and operations positions at Dutch Ophthalmic Research Center, an ophthalmic surgical-device company.

Scott's experience spans product launches, commercial strategy, marketing, and business operations—skills that are particularly valuable as EndoSound transitions from product development to commercial growth.

Aldrich earned a bachelor's degree in psychology from Amherst College.

Stephen Steinberg - Co-Founder & Chief Medical Officer

Stephen is the physician who conceived the idea behind EndoSound after decades of practicing gastroenterology. A specialist in advanced therapeutic endoscopy, he recognized that endoscopic ultrasound was one of the most valuable diagnostic tools available—but also one of the least accessible because of its high cost. That insight ultimately led him to found EndoSound.

He has spent more than 40 years performing advanced gastrointestinal procedures and currently serves as Director of the Center for Advanced Therapeutic Endoscopy at Boca Raton Regional Hospital. Over the course of his career, he has trained physicians, developed new endoscopic techniques, and become a recognized leader in therapeutic endoscopy.

As EndoSound's Chief Medical Officer, Stephen continues to guide the company's clinical strategy while working with physicians to bring its technology into everyday practice. His goal is to make advanced endoscopic ultrasound available to far more hospitals and surgery centers around the world.

He earned his medical degree from Cornell University and completed his gastroenterology training before building his long clinical career.

Scott Corbett - Co-Founder & CTO

Scott is the engineering force behind EndoSound's technology. With more than 30 years of experience in ultrasound engineering, he has spent his career designing medical imaging systems and developing new biomedical technologies. He co-founded EndoSound and serves as its Chief Technology Officer.

Before launching EndoSound, he co-founded MicroConnex, a manufacturer specializing in flexible electronic interconnects for medical devices. The company was successfully acquired by Carlisle Interconnect Technologies in 2019. Earlier in his career, Corbett held engineering and leadership positions at GE Medical Systems, Precision Interconnect, and Sonivate, building expertise in ultrasound technology and product development.

Scott has co-invented EndoSound's core technology and is listed as an inventor on numerous patents. He has also served on national committees responsible for establishing ultrasound safety and measurement standards, giving him deep technical expertise in the field.

He earned a bachelor's degree in physics from Occidental College and a master's degree in acoustics from Pennsylvania State University.

Co-Investors

Geo Med Tech

A European venture-capital firm.